Clinical Trial: Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07213973) titled 'Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa' on Oct. 07.

Brief Summary: The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.

Study Start Date: Dec. 14

Study Type: INTERVENTIONAL

Condition: Hidradenitis Suppurativa (HS)

Intervention: DRUG: Povorcitinib

Oral; Tablet

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Incyte Corporation

Disclaimer: Curated by HT Syndication....